BridgeBio Pharma (BBIO) Total Current Liabilities (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Total Current Liabilities data on file, last reported at $816.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 436.72% year-over-year to $816.4 million; the trailing twelve-month figure through Mar 2026 stood at $816.4 million (up 436.72% YoY), and the FY2025 full-year result was $288.0 million, up 86.51% from the prior year.
• Total Current Liabilities improved to $816.4 million in Q1 2026, from $288.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $816.4 million in Q1 2026 to a low of $96.6 million in Q1 2023.
• A 5-year average of $185.9 million and a median of $141.2 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slipped 21.99% in 2023 and surged 436.72% in 2026, its largest moves.
• Tracing BBIO's Total Current Liabilities over 5 years: stood at $121.4 million in 2022, then advanced by 18.46% to $143.8 million in 2023, then rose by 7.34% to $154.4 million in 2024, then jumped by 86.51% to $288.0 million in 2025, then soared by 183.49% to $816.4 million in 2026.
• Business Quant data shows BBIO's Total Current Liabilities at $816.4 million in Q1 2026, $288.0 million in Q4 2025, and $216.6 million in Q3 2025.